Stockreport

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of respon [Read more]